Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Ponders Whether To Publicly Discuss Pending NDAs And INDs; Should Agency Reply To Studies Published In Journals?

Executive Summary

FDA leadership is considering whether, and to what extent, the agency should be able to publicly discuss INDs, drug applications and complete response letters

You may also be interested in...

International Pharma Associations Lay Principles For Publishing Trial Data, Regardless Of Outcome

HONG KONG - Multinational pharmaceutical companies may start submitting for publication the results of more clinical trials, whether they are successful or not, as part of a new set of principles endorsed by industry associations around the world

Transparent Timing: Industry Will Soon Learn FDA Thinking On Releasing Info Now Kept Under Wraps

More transparency could help Freedom of Information Act process, FDA Deputy Commissioner Sharfstein suggests.

Jenkins Suggests "Complete Response" Letter Transparency Could Prompt Better Drug Applications, Faster Reviews

If FDA's transparency initiative results in the public release of "complete response" letters, Office of New Drugs Director John Jenkins sees a possible side benefit for the agency

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts